Phase 3 N=124 Randomized Quadruple-blind Treatment

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

Atopic Dermatitis

Bottom Line

View on ClinicalTrials.gov: NCT02595073 ↗

Enrolled (actual)

124

Serious AEs

0.0%

Results posted

Dec 2018

Primary outcome: Primary: The Number of Patients in Each Treatment Group That Have Clinical Success — 21; 27 Participants — p=0.3353

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: DSXS (Drug); Placebo (Drug)
Age: Pediatric, Adult, Older Adult · 0+ yrs
Sex: All
Sponsor: Sun Pharmaceutical Industries, Inc.
Primary completion: Jan 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY The Number of Patients in Each Treatment Group That Have Clinical Success	21; 27	0.3353
SECONDARY Change From Baseline in %BSA Affected at Day 28 ± 2	-13.81; -13.24	0.6190

Summary

Efficacy and Safety of DSXS (Taro Pharmaceuticals, U.S.A., Inc.) in Patients with Moderate to Severe Atopic Dermatitis

Eligibility Criteria

Inclusion Criteria

male and non-pregnant females, age 6 months or older, with a confirmed diagnosis of moderate to severe atopic dermatitis (AD)

Exclusion Criteria

Lacks stable diagnosis of atopic dermatitis or has been diagnosed with mild atopic dermatitis.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02595073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.